GlassScriptPhysician profile
Steven Cai
NPI 1053468868
$63,876.95
in general payments reported to CMS, 2019-2025
27 companies · $19K in 2025
The $19K reported for 2025 was more than what 97% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $153 · 2021: $730 · 2022: $5,271 · 2023: $18K · 2024: $20K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $7,505 · Food and Beverage: $5,827 · Entertainment: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,095.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,570.00 |
| Travel and Lodging | $7,505.22 |
| Food and Beverage | $5,826.51 |
| Entertainment | $127.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $24,701.51 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Hologic INC | $23,944.26 | 2021-2025 | Localizer, Biozorb, Magtrace |
| Endomagnetics LTD | $6,824.87 | 2019-2025 | Magseed, Magtrace, Sentimag |
| Hologic Sales and Service, LLC | $4,504.04 | 2023-2025 | Localizer, Sentimag, Magtrace |
| Myriad Genetic Laboratories, INC. | $533.77 | 2021-2024 | Myrisk |
| Stryker Corporation | $495.39 | 2021-2025 | 1788 |
| Leica Microsystems INC. | $352.00 | 2024-2025 | Mammotome Elite |
| Smith+Nephew, INC. | $345.61 | 2019-2024 | Collagenase Santyl |
| Davol INC. | $288.48 | 2025 | Phasix Mesh |
| Polynovo North America LLC | $242.83 | 2025 | Novosorb Btm |
| Dilon Technologies, INC. | $212.74 | 2023-2024 | Hemoblast Bellows |
| Lifenet Health | $156.11 | 2024 | Theragenesis Wound Matrix |
| Agios Pharmaceuticals, INC. | $155.59 | 2025 | Pyrukynd |
| Avita Medical Americas, LLC | $133.13 | 2024-2025 | Cohealyx, Recell, Permeaderm |
| Alexion Pharmaceuticals, INC. | $130.00 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kub Technologies INC. | $127.89 | 2023 | Mozart |
| Amgen INC. | $125.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $123.13 | 2023 | Tagrisso |
| Applied Medical Resources Corporation | $120.66 | 2025 | |
| Janssen Pharmaceuticals, INC | $120.03 | 2019 | |
| Biocircuit Technologies INC | $114.66 | 2024 | |
| Baxter Healthcare | $40.80 | 2025 | Artiss |
| Kci USA, INC. | $21.09 | 2020 | |
| Allergan, INC. | $17.30 | 2021 | |
| Convatec INC. | $16.88 | 2024 | |
| Solventum Corporation | $15.16 | 2024 | Prevena, Prevena Restor Bellaform |
| Cumberland Pharmaceuticals, INC. | $14.02 | 2024 | Caldolor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Cai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.